Literature DB >> 30478150

Targeting of BRM Sensitizes BRG1-Mutant Lung Cancer Cell Lines to Radiotherapy.

Erika Zernickel1, Ali Sak2, Assad Riaz2, Diana Klein3, Michael Groneberg2, Martin Stuschke2.   

Abstract

Targeting of epigenetic regulators as the chromatin remodeler SWI/SNF is proving to be a promising therapeutic strategy for individualized treatment of cancer patients. Here, we tested whether targeting one of the two mutually exclusive subdomains of the SWI/SNF complex BRM/SMARCA2 can sensitize specifically non-small cell lung carcinoma (NSCLC) cells with mutations in the other subunit BRG1/SMARCA4 toward ionizing radiation (IR). Knockdown of BRM with siRNA or shRNA and its consequences for radiation sensitivity as measured by clonogenic survival and plaque-monolayer control was studied in different NSCLC lines with or without BRG1 mutations and in primary fibroblasts. Furthermore, the effect on double-strand break (DSB) repair markers measured by immunofluorescence staining of 53BP1-, γ-H2AX-, and Rad51-foci was investigated. BRG1-mutated cell lines showed an increased surviving fraction compared with BRG1 proficient cells. Depletion of BRM (i) leads to a decreased proliferation rate and plating efficiency specifically in BRG1-mutated cells, (ii) specifically sensitized BRG1-mutant NSCLC cells toward IR as characterized by a survival reducing factor of 0.63 [95% confidence interval (CI), 0.57-0.69] in the dose range between 2 and 6 Gy, and (iii) decreased the tumor control doses after daily fractionation at 4 Gy in BRG1-mutant NSCLC cell lines A549 and H1299 in minimonolayers by 9.9% ± 1.3% and 13.6% ± 1.8%, respectively. In addition, an increase of residual Rad51-foci at 24 hours after irradiation in BRG1-mutant cells was demonstrated. Therefore, targeting of BRM in combination with radiotherapy is supposed to improve the therapeutic outcome of lung cancer patients harboring BRG1 mutations.The present study shows that the moderate radioresponsiveness of NSCLC cells with BRG1 mutations can be increased upon BRM depletion that is associated with a prolonged Rad51-foci prevalence at DNA DSBs. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30478150     DOI: 10.1158/1535-7163.MCT-18-0067

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  9 in total

Review 1.  COMPASS and SWI/SNF complexes in development and disease.

Authors:  Bercin K Cenik; Ali Shilatifard
Journal:  Nat Rev Genet       Date:  2020-09-21       Impact factor: 53.242

2.  The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer.

Authors:  Chai Bandlamudi; Jessica A Lavery; Joseph Montecalvo; Azadeh Namakydoust; Natasha Rekhtman; Gregory J Riely; Adam J Schoenfeld; Hira Rizvi; Jacklynn Egger; Carla P Concepcion; Sonal Paul; Maria E Arcila; Yahya Daneshbod; Jason Chang; Jennifer L Sauter; Amanda Beras; Marc Ladanyi; Tyler Jacks; Charles M Rudin; Barry S Taylor; Mark T A Donoghue; Glenn Heller; Matthew D Hellmann
Journal:  Clin Cancer Res       Date:  2020-07-24       Impact factor: 12.531

Review 3.  BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?

Authors:  Iga Jancewicz; Janusz A Siedlecki; Tomasz J Sarnowski; Elzbieta Sarnowska
Journal:  Epigenetics Chromatin       Date:  2019-11-13       Impact factor: 4.954

4.  Mechanism of miR-760 Reversing Lung Cancer Immune Escape by Downregulating IDO1 and Eliminating Regulatory T Cells Based on Mathematical Biology.

Authors:  Hong Ge; Lili Wang; Wenqiang Chen; Lei Wang
Journal:  Comput Math Methods Med       Date:  2022-07-14       Impact factor: 2.809

5.  Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy.

Authors:  Shan Xu; Ali Sak; Ben Niedermaier; Yasin Bahadir Erol; Michael Groneberg; Emil Mladenov; MingWei Kang; George Iliakis; Martin Stuschke
Journal:  Front Oncol       Date:  2022-09-30       Impact factor: 5.738

6.  Notable Response of SMARCA4-Deficient Undifferentiated Uterine Sarcoma to Palliative Radiation Therapy.

Authors:  Mariko Kurokawa; Takuya Shimizuguchi; Kei Ito; Maki Takao; Toru Motoi; Ayumi Taguchi; Toshiharu Yasugi; Katsuyuki Karasawa
Journal:  Adv Radiat Oncol       Date:  2021-05-25

7.  Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response.

Authors:  B Niedermaier; A Sak; E Zernickel; Shan Xu; M Groneberg; M Stuschke
Journal:  Sci Rep       Date:  2019-12-03       Impact factor: 4.379

Review 8.  A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance.

Authors:  Isabell Götting; Verena Jendrossek; Johann Matschke
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

Review 9.  Oncometabolites and the response to radiotherapy.

Authors:  Kexu Xiang; Verena Jendrossek; Johann Matschke
Journal:  Radiat Oncol       Date:  2020-08-14       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.